WO2002043766A1 - Medicinal compositions and process for producing the same - Google Patents

Medicinal compositions and process for producing the same Download PDF

Info

Publication number
WO2002043766A1
WO2002043766A1 PCT/JP2001/010417 JP0110417W WO0243766A1 WO 2002043766 A1 WO2002043766 A1 WO 2002043766A1 JP 0110417 W JP0110417 W JP 0110417W WO 0243766 A1 WO0243766 A1 WO 0243766A1
Authority
WO
WIPO (PCT)
Prior art keywords
producing
same
medicinal compositions
antagonist
nonpeptidic
Prior art date
Application number
PCT/JP2001/010417
Other languages
French (fr)
Japanese (ja)
Inventor
Yutaka Yamagata
Yoshio Hata
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU2002218494A priority Critical patent/AU2002218494A1/en
Publication of WO2002043766A1 publication Critical patent/WO2002043766A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Compositions wherein the release of a nonpeptidic GnRH agonist and antagonist having a particularly low solubility is accelerated. Namely, compositions containing a hardly water-soluble nonpeptidic gonadotropin-releasing hormone agonist or antagonist and an aromatic hydroxycarboxylic acid or its salt.
PCT/JP2001/010417 2000-11-29 2001-11-29 Medicinal compositions and process for producing the same WO2002043766A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002218494A AU2002218494A1 (en) 2000-11-29 2001-11-29 Medicinal compositions and process for producing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-362727 2000-11-29
JP2000362727 2000-11-29

Publications (1)

Publication Number Publication Date
WO2002043766A1 true WO2002043766A1 (en) 2002-06-06

Family

ID=18833953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010417 WO2002043766A1 (en) 2000-11-29 2001-11-29 Medicinal compositions and process for producing the same

Country Status (2)

Country Link
AU (1) AU2002218494A1 (en)
WO (1) WO2002043766A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002092A3 (en) * 2001-06-29 2003-04-10 Takeda Chemical Industries Ltd Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
WO2003064429A1 (en) * 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
WO2004067535A1 (en) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
EP2329823A1 (en) * 2008-09-03 2011-06-08 Takeda Pharmaceutical Company Limited Method for improving absorbability of preparation, and preparation having improved absorbability
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5734822B2 (en) * 1975-02-12 1982-07-26
JPS6393714A (en) * 1986-10-09 1988-04-25 Sekisui Chem Co Ltd Plaster for transcutaneous absorption
EP0503583A1 (en) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Composition for sustained release of erythropoietin
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
WO1994025460A1 (en) * 1993-04-28 1994-11-10 Janssen Pharmaceutica N.V. Risperidone pamoate
JPH07196510A (en) * 1993-12-28 1995-08-01 Nippon Seiyaku Kk A sustained release lipid emulsion for analgesic-containing injection solution
WO1995028405A1 (en) * 1994-04-19 1995-10-26 Takeda Chemical Industries, Ltd. Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists
JPH1045616A (en) * 1996-08-02 1998-02-17 Shionogi & Co Ltd Sustained release preparation for injection
WO1998032423A1 (en) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
WO1999036099A1 (en) * 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
JPH11199521A (en) * 1997-12-26 1999-07-27 Lion Corp Preparation for external use for skin
WO2000056739A1 (en) * 1999-03-24 2000-09-28 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5734822B2 (en) * 1975-02-12 1982-07-26
JPS6393714A (en) * 1986-10-09 1988-04-25 Sekisui Chem Co Ltd Plaster for transcutaneous absorption
EP0503583A1 (en) * 1991-03-12 1992-09-16 Takeda Chemical Industries, Ltd. Composition for sustained release of erythropoietin
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
WO1994025460A1 (en) * 1993-04-28 1994-11-10 Janssen Pharmaceutica N.V. Risperidone pamoate
JPH07196510A (en) * 1993-12-28 1995-08-01 Nippon Seiyaku Kk A sustained release lipid emulsion for analgesic-containing injection solution
WO1995028405A1 (en) * 1994-04-19 1995-10-26 Takeda Chemical Industries, Ltd. Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists
JPH1045616A (en) * 1996-08-02 1998-02-17 Shionogi & Co Ltd Sustained release preparation for injection
WO1998032423A1 (en) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
JPH11199521A (en) * 1997-12-26 1999-07-27 Lion Corp Preparation for external use for skin
WO1999036099A1 (en) * 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
WO2000056739A1 (en) * 1999-03-24 2000-09-28 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067030B2 (en) 2001-06-29 2011-11-29 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
US8815801B2 (en) 2001-06-29 2014-08-26 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
EP1491236A1 (en) * 2001-06-29 2004-12-29 Takeda Chemical Industries, Ltd. Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
US8246987B2 (en) 2001-06-29 2012-08-21 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
WO2003002092A3 (en) * 2001-06-29 2003-04-10 Takeda Chemical Industries Ltd Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
US7429559B2 (en) 2001-06-29 2008-09-30 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
EP1949936A3 (en) * 2001-06-29 2008-10-08 Takeda Pharmaceutical Company Limited Controlled release composition and method of producing the same
WO2003064429A1 (en) * 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
CN100360538C (en) * 2003-01-29 2008-01-09 武田药品工业株式会社 Thienopyrimidine compound and use of the same
KR101074462B1 (en) * 2003-01-29 2011-10-18 다케다 야쿠힌 고교 가부시키가이샤 Thienopyrimidine compounds and use thereof
US8058280B2 (en) 2003-01-29 2011-11-15 Takeda Pharmaceutical Company Limited Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
US8735401B2 (en) 2003-01-29 2014-05-27 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
WO2004067535A1 (en) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
US9346822B2 (en) 2003-01-29 2016-05-24 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
US8921326B2 (en) 2006-12-18 2014-12-30 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
US9617303B2 (en) 2006-12-18 2017-04-11 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
US9713595B2 (en) 2006-12-18 2017-07-25 Takeda Pharmaceuticals Company Limited Sustained-release composition and method for producing the same
EP2329823A1 (en) * 2008-09-03 2011-06-08 Takeda Pharmaceutical Company Limited Method for improving absorbability of preparation, and preparation having improved absorbability
EP2329823A4 (en) * 2008-09-03 2013-04-03 Takeda Pharmaceutical Method for improving absorbability of preparation, and preparation having improved absorbability

Also Published As

Publication number Publication date
AU2002218494A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
AU2001279710A1 (en) Magnesium-ammonium-phosphate cements, the production of the same and the use thereof
EP1419776A3 (en) Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AU6051800A (en) Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
ZA200301813B (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
AU2001266075A1 (en) Combinations of active ingredients, which exhibit insecticidal and acaricidal properties
AU2001278986A1 (en) 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
WO2002016312A3 (en) NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
EP2452684A3 (en) Micelles
AU2002323873A1 (en) Active ingredient combination of E.G. galanthamine or deoxypeganine and E.G. acamprosate or memantine for treating an addiction such as alcoholism
EP1600441A3 (en) Novel crystalline form of lercanidipin hydrochloride and processes for its preparation
WO2002043766A1 (en) Medicinal compositions and process for producing the same
WO2003024933A1 (en) 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
EP1250937A3 (en) Controlled dissolution of active ingredients
AU6386801A (en) System for the release of active ingredients
WO2002015892A3 (en) Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
WO2001078654A3 (en) Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AU2001256324A1 (en) Process for the preparation of alkaline earth salts of d-pantothenic acid
AU2002239438A1 (en) 2,4-hexadienoic acid and derivatives as corrosion inhibitors
WO2002076376A3 (en) A stable pharmaceutical composition of pravastatin
AU2624101A (en) Galvanic methods of accelerating copper dissolution into solutions containing nitrogen compounds
WO2002050241A3 (en) Antimicrobial wipe
AU3413399A (en) Device for locating locking holes of implants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP